CURRENT
ISSUE
1610

Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.

INDICATIONS FOR TREATMENT — Antiviral treatment can be considered for otherwise healthy symptomatic outpatients with suspected or confirmed...  Continue reading

More from Issue 1610
Previous Issue: 1609      October 19, 2020
Coming Soon
Drugs for Asthma
In Brief: Hydrochlorothiazide and Skin Cancer
Empagliflozin (Jardiance) for Heart Failure
Orphengesic Forte - An Old Analgesic Combination Returns
Remdesivir (Veklury) for COVID-19
Ashwagandha Supplements
Ofatumumab (Kesimpta) for Multiple Sclerosis
New Meningococcal Vaccination Recommendations
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1610

The short-acting beta2-agonist albuterol sulfate has recently become available as a large-volume (20 mL), preservative-free concentrate (albuterol inhalation solution 0.5% – Nephron Pharmaceuticals) that can be used to prepare solutions for administration of continuous nebulized albuterol (CNA). CNA is commonly used (off-label) for acute treatment of severe asthma exacerbations in hospitalized patients, particularly children.1 ... Continue reading

 Tweets